Visiongain publishes Amyotrophic Lateral Sclerosis (ALS) Market Report 2020-2030

22 June 2020
Pharma

Visiongain has launched a new report Amyotrophic Lateral Sclerosis (ALS) Market Report 2020-2030: Forecasts by Treatment (Medication, Stem Cell Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography PLUS Profiles of Leading Companies.

The global Amyotrophic Lateral Sclerosis (ALS) market is anticipated to grow at a lucrative CAGR of more than xyz% and anticipated to cross USD xyz million by 2030. The factors driving this demand are raising geriatric population, growing knowledge of ALS and increasing incidence rate. However, during the projected era, the high cost associated with ALS treatment may pose an impediment for the industry.

To access the data contained in this document please email contactus@visiongain.com

In terms of region, North America currently holds the largest share of over 50% in ALS market owing to the presence of significant number of patients within the region. Availability of medicines as well as other therapies within the region for disease management is the major reasons for high market share. The factors driving the industry are rise in healthcare spending, attractive reimbursement programs, massive demand for ALS medications and the existing healthcare infrastructure. In 2018, prevalence of ALS in the United States is 5 was 100,000, according to data released in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Study.

Over the projected era, Asia Pacific is predicted to experience the highest growth rate among all regions. In this area, particularly in India and China, the industry is witnessing a growing revenue generation from Riluzole generic manufacturers. Several of the main drivers of demand growth in this area include increasing R&D spending in the healthcare industry, and rise in number of producers and government’s initiatives.

Key vendors in the market include Mitsubishi Tanabe Pharma Corporation, Biohaven Pharmaceutical, AB Science, F.Hoffmann-La Roche AG, and Sun Pharmaceutical. Stem cell therapy providers are also actively performing trials to name a few, BrainStorm Cell Therapeutics, Seneca Biopharma, CORESTEM and many more. However, the Rilutek patent, which was introduced in 1995, expired in 2013, contributing to the development of cheap generic copies of the medication. Companies are pursuing different approaches to achieve a competitive edge, such as innovative product growth, penetration into developing counties and strategic alliances.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

Read

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever